Hyperlipidaemia

• EMA approval · 2026-01-09
  EMA Authorised: Praluent (alirocumab) — Sanofi Winthrop Industrie

  The European Medicines Agency has authorised Praluent (alirocumab) for dyslipidaemias, with Sanofi Winthrop Industrie as the marketing autho…

• CLINICAL_TRIALS trial_result · 2023-12-15
  Clinical Trial Update: A Study to Assess the Safety, Efficacy and Tolerability of AZD8233 Treatment in Participants With Hyperlipidaemia [Phase 2]

  Phase 2 trial evaluating safety, efficacy, and tolerability of AZD8233 in participants with hyperlipidaemia has completed with results poste…